Veristat announced that it has entered into an agreement to acquire the Regulatory and Medical Writing business of Certara, strengthening its position in regulatory services and clinical development support.
The transaction will add more than 200 experts to Veristat’s platform, significantly expanding its capabilities in regulatory writing, submission strategy, and advisory services. The acquired team is known for its expertise in producing clinical and non-clinical documentation across the drug development lifecycle, enhancing Veristat’s ability to support complex therapies.
The acquisition is backed by WindRose Health Investors, which continues to support Veristat’s growth strategy as it scales its service offerings in the life sciences sector.
Veristat, a full-service contract research organization and consultancy, focuses on advancing therapies from early development through regulatory submission. The integration of Certara’s regulatory and medical writing business is expected to create a more comprehensive platform spanning biostatistics, regulatory affairs, and clinical documentation.
The combined capabilities are designed to help pharmaceutical and biotechnology companies navigate increasingly complex regulatory environments, particularly in areas such as rare diseases, oncology, neurological disorders, and advanced therapies. By enhancing its service offering, Veristat aims to accelerate the development and approval of new treatments for patients with unmet medical needs.
The transaction is expected to close in the second quarter of 2026, subject to customary conditions. Until completion, both companies will continue operating independently.
The deal reflects broader consolidation within the contract research and life sciences services sector, as companies seek to build integrated platforms capable of supporting the full drug development lifecycle.
KEY QUOTES:
“Over the past 30+ years, Veristat has strategically invested in organizations, people, and resources to help our clients solve their most complex clinical development, regulatory, and commercialization challenges. By combining our complementary strengths and talented teams, Veristat will have unmatched capabilities in biostats, medical writing, and regulatory affairs, made even stronger by a shared focus on science-based insights, strong client partnerships, innovation, and impact. We will be able to bring even more life-changing medical therapies to patients with unmet needs, and that’s an exciting prospect for all of us.”
Kim Boericke, Chief Executive Officer, Veristat
